Corrigendum to "High-Dose Polymerized Hemoglobin Fails to Alleviate Cardiac Ischemia/Reperfusion Injury due to Induction of Oxidative Damage in Coronary Artery".

Qian Yang,Yanhua Qiu,Qian Li,Jiaxin Liu,Ronghua Zhou,Zhaoxia Tan,Jin Liu,Tao Li,Chengmin Yang,Ming Luo,Gang Chen,Shen Li,Wentao Zhou,Chan Chen,Wei Wu

doi:10.1155/2019/4576867

Abstract

[This corrects the article DOI: 10.1155/2015/125106.].

Highlights

Ischemia/reperfusion (I/R) injury is harmful to cardiovascular system and responsible to cardiac infarction, which is thought to be involved in the severity and outcome of ischemic heart disease [1]
In addition to cardiac I/R injury, cardiopulmonary bypass (CPB) is usually companied with a reduction in hemoglobin level because of the colloid solution primed in CPB circuit and unexpected blood loss after heparinization
A clear cardioprotection is observed in the low-dose polymerized human placenta hemoglobin (PolyPHb) group, suggesting the in vivo cardiac effect of hemoglobin-based oxygen carrier (HBOC) is highly correlated to its dosage

Summary

Introduction

Ischemia/reperfusion (I/R) injury is harmful to cardiovascular system and responsible to cardiac infarction, which is thought to be involved in the severity and outcome of ischemic heart disease [1]. Our previous work and other studies indicated that HBOCs are promising candidates to prevent many organs from I/R injury [4,5,6,7]. They allow delivery of more oxygen (O2) to hypoxic tissues due to their

Methods

Results

Conclusion